The 6 analysts offering 12-month price forecasts for OncoCyte Corp have a median target of 2.30, with a high estimate of 4.00 and a low estimate of 1.15. The median estimate represents a +205.81% increase from the last price of 0.75.
The current consensus among 7 polled investment analysts is to Buy stock in OncoCyte Corp. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.11
Reporting Date Nov 17
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.